JP2003505420A - 咳を処置するのに使用するノシセプチンレセプタorl−1 - Google Patents

咳を処置するのに使用するノシセプチンレセプタorl−1

Info

Publication number
JP2003505420A
JP2003505420A JP2001511934A JP2001511934A JP2003505420A JP 2003505420 A JP2003505420 A JP 2003505420A JP 2001511934 A JP2001511934 A JP 2001511934A JP 2001511934 A JP2001511934 A JP 2001511934A JP 2003505420 A JP2003505420 A JP 2003505420A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
hydrogen
phenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001511934A
Other languages
English (en)
Japanese (ja)
Inventor
ディーン チュールシアン,
ジニー ディー. ホ,
リサ エス. シルバーマン,
ジュリアス ジェイ. マテイシ,
ロビー エル. マックラウド,
ジョン エイ. ヘイ,
リチャード ダブリュー. チャプマン,
アナ バーコビチ,
フランシス エム. カス,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2003505420A publication Critical patent/JP2003505420A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
JP2001511934A 1999-07-26 2000-01-26 咳を処置するのに使用するノシセプチンレセプタorl−1 Pending JP2003505420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/359,771 US6262066B1 (en) 1998-07-27 1999-07-26 High affinity ligands for nociceptin receptor ORL-1
US09/359,771 1999-07-26
PCT/US2000/001853 WO2001007050A1 (en) 1999-07-26 2000-01-26 Nociceptin receptor orl-1 agonists for use in treating cough

Publications (1)

Publication Number Publication Date
JP2003505420A true JP2003505420A (ja) 2003-02-12

Family

ID=23415204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001511934A Pending JP2003505420A (ja) 1999-07-26 2000-01-26 咳を処置するのに使用するノシセプチンレセプタorl−1

Country Status (13)

Country Link
US (4) US6262066B1 (US06262066-20010717-C00461.png)
EP (1) EP1200087A1 (US06262066-20010717-C00461.png)
JP (1) JP2003505420A (US06262066-20010717-C00461.png)
CN (1) CN1374865A (US06262066-20010717-C00461.png)
AU (1) AU2629800A (US06262066-20010717-C00461.png)
BR (1) BR0012801A (US06262066-20010717-C00461.png)
CA (1) CA2379398A1 (US06262066-20010717-C00461.png)
HK (1) HK1042236A1 (US06262066-20010717-C00461.png)
HU (1) HUP0203458A3 (US06262066-20010717-C00461.png)
MX (1) MXPA02001033A (US06262066-20010717-C00461.png)
NO (1) NO20020392L (US06262066-20010717-C00461.png)
WO (1) WO2001007050A1 (US06262066-20010717-C00461.png)
ZA (1) ZA200200275B (US06262066-20010717-C00461.png)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037269A1 (ja) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
JP2009513655A (ja) * 2005-10-27 2009-04-02 シェーリング コーポレイション ノシセプチンレセプターorl−1のリガンドとしての8−[ビス−(2−クロロ−フェニル)−メチル]−3−フェニル−8−アザ−ビシクロ[3.2.1]オクタン−3−カルボン酸アミド
JP2010516687A (ja) * 2007-01-16 2010-05-20 パーデュー、ファーマ、リミテッド、パートナーシップ 複素環置換ピペリジン化合物とその使用
JP2010523687A (ja) * 2007-04-09 2010-07-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのorl−1受容体リガンドとしての1,3,8−三置換−1,3,8−トリアザ−スピロ[4.5]デカン−4−オン誘導体
JP5313865B2 (ja) * 2007-03-01 2013-10-09 田辺三菱製薬株式会社 ベンゾイミダゾール化合物およびその医薬用途
JP2016508142A (ja) * 2012-12-31 2016-03-17 サノビオン・ファーマシューティカルズ・インコーポレイテッドSunovion Pharmaceuticals Inc. 複素環式化合物及びその使用方法
JP2020517745A (ja) * 2017-04-19 2020-06-18 ナショナル ユニヴァーシティ オブ シンガポール Bcl−2関連死プロモーター(bad)のリン酸化の小分子阻害剤

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
DE60022226D1 (de) * 1999-12-06 2005-09-29 Euro Celtique Sa Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
EP1537110B1 (en) * 1999-12-06 2007-01-17 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
DE20005049U1 (de) * 2000-03-20 2000-05-18 Dewert Antriebs Systemtech Elektromotorische Antriebseinheit
MXPA03009239A (es) * 2001-04-10 2004-11-12 Johnson & Johnson Derivados de 1,3,8-triazapiro[4,5]decan-4-ona utiles para el tratamiento de trastornos mediados por el receptor orl-1.
DE60235617D1 (de) * 2001-04-12 2010-04-22 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
PT1385518E (pt) 2001-04-18 2008-10-07 Euro Celtique Sa Compostos de benzimidazolona
MXPA03009600A (es) 2001-04-18 2004-04-02 Euro Celtique Sa Analogos de nociceptina.
WO2002085354A1 (en) * 2001-04-18 2002-10-31 Euro-Celtique S.A. Spiroindene and spiroindane compounds
JP4380992B2 (ja) 2001-04-18 2009-12-09 ユーロ−セルティーク エス.エイ. ノシセプチン類似体
US6635653B2 (en) 2001-04-18 2003-10-21 Euro-Celtique S.A. Spiropyrazole compounds
WO2002088089A1 (fr) * 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
WO2002100861A1 (en) * 2001-06-13 2002-12-19 Akzo Nobel N.V. 1-(3-phenyloxypropyl)piperidine derivatives
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
CA2490386A1 (en) * 2001-07-02 2003-01-16 Omeros Corporation Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist
FR2827282B1 (fr) * 2001-07-16 2004-08-13 Sanofi Synthelabo Procede pour la preparation de 4-amino-4-phenylpiperidines
FR2827281B1 (fr) * 2001-07-16 2003-12-19 Sanofi Synthelabo Procede pour la preparation de la 4-methylamino-4-phenylpiperidine
AU2002343489A1 (en) 2001-10-09 2003-04-22 Synvax, Inc. Nociceptin-based analgesics
MY126268A (en) * 2001-11-07 2006-09-29 Schering Corp Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
AR037364A1 (es) 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US7652039B2 (en) 2002-05-17 2010-01-26 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious disease
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
US20040072809A1 (en) 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method
ATE416162T1 (de) * 2002-08-29 2008-12-15 Astrazeneca Ab Naphthamidderivate und deren verwendung
WO2004022558A2 (en) * 2002-09-09 2004-03-18 Janssen Pharmaceutica, N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
US7045527B2 (en) 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
AR045913A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
SA04250305B1 (ar) * 2003-09-25 2008-06-02 سولفاي فارماسوتيكالز بي . في مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية
WO2005037280A1 (en) * 2003-10-14 2005-04-28 Glaxo Group Limited Muscarinic acetycholine receptor antagonists
JP2007509061A (ja) * 2003-10-17 2007-04-12 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
WO2005095407A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
UY28871A1 (es) * 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2006031788A2 (en) * 2004-09-15 2006-03-23 Schering-Plough Ltd. Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
EP2522669B1 (en) * 2005-06-02 2016-12-28 Janssen Pharmaceutica NV 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
ATE550338T1 (de) 2005-07-18 2012-04-15 Merck Sharp & Dohme Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
US20080275079A1 (en) * 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
WO2007016650A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EP1943250A1 (en) 2005-09-09 2008-07-16 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Pgd2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
PE20071159A1 (es) * 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
EP1987009A1 (en) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
CA2654262A1 (en) * 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
JP2010502705A (ja) * 2006-09-07 2010-01-28 メルク エンド カムパニー インコーポレーテッド アルツハイマー病の治療用としてのスピロピペリジンベータセクレターゼ阻害剤
WO2008067167A1 (en) * 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
RU2488585C2 (ru) 2007-08-31 2013-07-27 Пэдью Фарма Л.П. Замещенные пиперидиновые соединения хиноксалинового типа и их применение
RS53552B1 (en) 2007-10-11 2015-02-27 Astrazeneca Ab DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B
MX2011000872A (es) 2008-07-21 2011-07-29 Purdue Pharma Lp Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos.
AU2009318855A1 (en) * 2008-11-23 2010-05-27 Pfizer Inc. Lactams as beta secretase inhibitors
ITNA20090026A1 (it) * 2009-05-14 2010-11-15 Agostino Bruno D Agonisti del recettore nop e loro usi terapeutici
RU2012106820A (ru) * 2009-07-27 2013-09-10 Трайджемина Инк. Способы лечения боли
WO2011099980A1 (en) 2010-02-12 2011-08-18 The Johns Hopkins University Use of the lactosylceramide synthase isoform b1, 4galt-v as a biomarker for cancer
CA2831848C (en) 2011-04-01 2020-12-22 Astrazeneca Ab Combination comprising (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide and a taxane
FI2785349T4 (fi) 2011-11-30 2023-02-09 Syövän yhdistelmähoito
US9290488B2 (en) 2011-12-01 2016-03-22 Purdue Pharma L.P. Azetidine-substituted quinoxalines as opioid receptor like-1 modulators
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CN104302623A (zh) * 2012-05-01 2015-01-21 住友化学株式会社 哌啶化合物及其有害生物防除用途
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9040533B2 (en) * 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN107847552B (zh) 2015-01-07 2022-07-01 三叉神经股份公司 含镁的催产素制剂和使用方法
EP3430007A1 (en) * 2016-03-15 2019-01-23 The Scripps Research Institute Signaling-biased mu opioid receptor agonists
WO2023284834A1 (zh) 2021-07-14 2023-01-19 宜昌人福药业有限责任公司 一种哌啶衍生物及其药物组合物、制备方法和用途
IT202200011057A1 (it) * 2022-05-26 2023-11-26 Univ Degli Studi Della Campania Luigi Vanvitelli Carriers nanotecnologici degli agonisti del recettore nop

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633914A (US06262066-20010717-C00461.png) * 1962-06-22
GB1052302A (US06262066-20010717-C00461.png) * 1963-04-22
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3311264A (en) 1964-12-14 1967-03-28 Arthur W Cayer Measuring and dispensing device
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
US4521537A (en) 1982-08-20 1985-06-04 Hoechst-Roussel Pharmaceuticals Incorporated Spiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine and -3'-pyrrolidine] compounds and their use as antihypertensive agents
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
JPS61225167A (ja) 1985-03-28 1986-10-06 Yoshitomi Pharmaceut Ind Ltd ベンゾ〔g〕キノリン誘導体
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE69129257T2 (de) 1990-10-12 1998-11-05 Merck Frosst Canada Inc Ungesättigte Hydroxyalkylchinolinsäuren als Leukotrien-Antagonisten
GB9100505D0 (en) 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
US5583000A (en) 1991-09-03 1996-12-10 The Regents Of The University Of California Protease-binding compounds and methods of use
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5472964A (en) 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
CA2166975C (en) * 1993-07-16 2005-04-05 Mark G. Bock Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
US5495052A (en) * 1994-09-29 1996-02-27 Arco Chemical Technology, L.P. Process for producing enantiomerically enriched guaifenesin
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE19519245C2 (de) 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0742208A1 (en) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
CZ248798A3 (cs) 1996-02-08 1999-01-13 Merck And Co., Inc. Farmaceutický prostředek
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
EP0921125B1 (en) 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
US6423725B1 (en) 1998-01-19 2002-07-23 Pfizer Inc 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
DE69923744T2 (de) * 1998-10-23 2006-02-23 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
MY126268A (en) * 2001-11-07 2006-09-29 Schering Corp Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037269A1 (ja) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
JP2009513655A (ja) * 2005-10-27 2009-04-02 シェーリング コーポレイション ノシセプチンレセプターorl−1のリガンドとしての8−[ビス−(2−クロロ−フェニル)−メチル]−3−フェニル−8−アザ−ビシクロ[3.2.1]オクタン−3−カルボン酸アミド
JP2010516687A (ja) * 2007-01-16 2010-05-20 パーデュー、ファーマ、リミテッド、パートナーシップ 複素環置換ピペリジン化合物とその使用
JP5313865B2 (ja) * 2007-03-01 2013-10-09 田辺三菱製薬株式会社 ベンゾイミダゾール化合物およびその医薬用途
JP2010523687A (ja) * 2007-04-09 2010-07-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのorl−1受容体リガンドとしての1,3,8−三置換−1,3,8−トリアザ−スピロ[4.5]デカン−4−オン誘導体
JP2016508142A (ja) * 2012-12-31 2016-03-17 サノビオン・ファーマシューティカルズ・インコーポレイテッドSunovion Pharmaceuticals Inc. 複素環式化合物及びその使用方法
JP2020517745A (ja) * 2017-04-19 2020-06-18 ナショナル ユニヴァーシティ オブ シンガポール Bcl−2関連死プロモーター(bad)のリン酸化の小分子阻害剤
JP7423010B2 (ja) 2017-04-19 2024-01-29 ナショナル ユニヴァーシティ オブ シンガポール Bcl-2関連死プロモーター(bad)のリン酸化の小分子阻害剤

Also Published As

Publication number Publication date
CN1374865A (zh) 2002-10-16
AU2629800A (en) 2001-02-13
MXPA02001033A (es) 2002-08-20
US6716846B2 (en) 2004-04-06
NO20020392L (no) 2002-03-25
HK1042236A1 (zh) 2002-08-09
EP1200087A1 (en) 2002-05-02
HUP0203458A2 (hu) 2003-02-28
ZA200200275B (en) 2003-06-25
CA2379398A1 (en) 2001-02-01
US20040152707A1 (en) 2004-08-05
WO2001007050A1 (en) 2001-02-01
NO20020392D0 (no) 2002-01-25
US6455527B2 (en) 2002-09-24
US6262066B1 (en) 2001-07-17
BR0012801A (pt) 2002-05-07
US20010011092A1 (en) 2001-08-02
US7094784B2 (en) 2006-08-22
HUP0203458A3 (en) 2004-01-28
US20030073690A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
JP2003505420A (ja) 咳を処置するのに使用するノシセプチンレセプタorl−1
RU2237060C2 (ru) Соединение, фармацевтическая композиция
JPH06504292A (ja) キヌクリジン誘導体
US20040067950A1 (en) High affinity ligands for nociceptin receptor ORL-1
EP1444200B1 (en) Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
US7485650B2 (en) High affinity ligands for nociceptin receptor ORL-1
MXPA01001025A (en) High affinity ligands for nociceptin receptor orl-1

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070927